The epidemiology of hepatitis C in a UK health regional population of 5.12 million

Gut

Volumn 48, Issue 5, 2001, Pages 707-713

  Mohsen, A H ^a   Green, S T ^a   Irving, W L ^a   Jones, D A ^a   McKendrick, M W ^a   Mohsen, A ^a   Neal, K R ^a   Ryder, S D ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Epidemiology; Hepatitis C

Indexed keywords

INTERFERON;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CAUSE OF DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HEMOPHILIA; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; UNITED KINGDOM;

ADULT; AGED; ALCOHOL DRINKING; BIOPSY; COHORT STUDIES; DISEASE PROGRESSION; ENGLAND; FEMALE; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 0035039269     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.48.5.707     Document Type: Article

References (37)

1. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome
2. Epidemiology of hepatitis C in the West
3. Post-transfusion hepatitis in Toronto, Canada
4. Hepatitis C: Global update
5. High seroprevalence of hepatitis A, B, C and E virus in residents in an Egyptian village in the Nile Delta
6. The prevalence of hepatitis B and C in an antenatal population of various ethnic origins
7. Transmission of hepatitis C virus by organ transplantation in the United Kingdom
8. Hepatitis C virus: Eight years old
9. Natural history of liver fibrosis progression in patients with chronic hepatitis C
10. Clinical outcomes after transfusion-associated hepatitis C
11. Rising incidence of hepatocellular carcinoma in the United States
12. Liver transplantation for chronic viral hepatitis
13. Chronic hepatitis in UK blood donors infected with hepatitis C virus
14. The most prevalent HCV genotypes in England and Wales are 3a and 1a
15. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent region (UK)
16. Formulation and application of a numerical scoring system for assessing histopathological activity in asymptomatic chronic active hepatitis
17. The natural history of community-acquired hepatitis C in the United States
18. Estimating the population prevalence of injection drug use and infection with human immunodeficiency virus among injecting drug users in Glasgow, Scotland
19. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
20. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
21. Hepatitis C virus antibody prevalence among injecting users in Glasgow has fallen but remains high
22. The risk of transfusion-transmitted viral infection
23. Risk factors associated with chronic hepatitis C virus infection: Limited frequency of unidentified source of transmission
24. Technology, experimentation, and the quality of survey data
25. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
26. Genetic heterogeneity of hepatitis C virus: Quasi-species and genotypes
27. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of case-control study
28. Hepatitis C in the United States: Epidemiology, pathogenicity, and response to interferon therapy
29. Impact of alcohol on the histological and clinical progression of hepatitis C infection
30. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
31. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis C: Effect of dose and duration
32. Management of chronic hepatitis C: Clinical audit of biopsy based management algorythm
33. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
34. Long-term mortality after transfusion-associated non-A, non-B hepatitis
35. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994